No. Working around this takes some effort but is straightforward and uses well-known, existing techniques. There's a lab I know of that considered trying to modify the protein so it could evade the immune system, but they decided against it since they figured the group that published this paper would have too much of a head start and there's no way they'd be able to compete. I'd give it a year or so, and that's assuming none of the other Cas9 or Cas12a variants are already usable.